Article
China-Based Biotech Selects Medidata Platform
Henlius Biotechnology has selected Medidata’s Medidata Clinical Cloud® platform for its Phase III oncology clinical trial in China.
China-based Shanghai Henlius Biotechnology Co. Ltd. (Henlius) has selected Medidata’s Medidata Clinical Cloud® platform, specifically Medidata Rave® (electronic data capture) and Medidata Balance® (randomization and trial supply management) in its Phase III oncology clinical trial in China.
Henlius focuses on the development, production and commercialization of monoclonal antibody drugs for a number of therapeutic areas, including oncology and auto-immune diseases.
Read the full release.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
